Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer

G. G. Steger, C. Dittrich, O. Schlappack, R. Mader, C. Herold, W. P. Brade, A. Keller, K. Moser

Research output: Contribution to journalArticle

Abstract

Twenty-six cycles of high-dose ifosfamide+mesna (HD-IFO+M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO+M over 24 h appeared to be the best tolerated. On partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.

Original languageEnglish (US)
Pages (from-to)602-604
Number of pages3
JournalJournal of Cancer Research and Clinical Oncology
Volume114
Issue number6
DOIs
StatePublished - Dec 1988
Externally publishedYes

Fingerprint

Mesna
Salvage Therapy
Ifosfamide
Breast Neoplasms
Appointments and Schedules
Therapeutics

Keywords

  • Breast cancer
  • Ifosfamide+mesna
  • Salvage therapy
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Steger, G. G., Dittrich, C., Schlappack, O., Mader, R., Herold, C., Brade, W. P., ... Moser, K. (1988). Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer. Journal of Cancer Research and Clinical Oncology, 114(6), 602-604. https://doi.org/10.1007/BF00398184

Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer. / Steger, G. G.; Dittrich, C.; Schlappack, O.; Mader, R.; Herold, C.; Brade, W. P.; Keller, A.; Moser, K.

In: Journal of Cancer Research and Clinical Oncology, Vol. 114, No. 6, 12.1988, p. 602-604.

Research output: Contribution to journalArticle

Steger, GG, Dittrich, C, Schlappack, O, Mader, R, Herold, C, Brade, WP, Keller, A & Moser, K 1988, 'Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer', Journal of Cancer Research and Clinical Oncology, vol. 114, no. 6, pp. 602-604. https://doi.org/10.1007/BF00398184
Steger, G. G. ; Dittrich, C. ; Schlappack, O. ; Mader, R. ; Herold, C. ; Brade, W. P. ; Keller, A. ; Moser, K. / Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer. In: Journal of Cancer Research and Clinical Oncology. 1988 ; Vol. 114, No. 6. pp. 602-604.
@article{fcd6a876e2984727b922c4f0a1b41550,
title = "Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer",
abstract = "Twenty-six cycles of high-dose ifosfamide+mesna (HD-IFO+M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO+M over 24 h appeared to be the best tolerated. On partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.",
keywords = "Breast cancer, Ifosfamide+mesna, Salvage therapy, Toxicity",
author = "Steger, {G. G.} and C. Dittrich and O. Schlappack and R. Mader and C. Herold and Brade, {W. P.} and A. Keller and K. Moser",
year = "1988",
month = "12",
doi = "10.1007/BF00398184",
language = "English (US)",
volume = "114",
pages = "602--604",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer

AU - Steger, G. G.

AU - Dittrich, C.

AU - Schlappack, O.

AU - Mader, R.

AU - Herold, C.

AU - Brade, W. P.

AU - Keller, A.

AU - Moser, K.

PY - 1988/12

Y1 - 1988/12

N2 - Twenty-six cycles of high-dose ifosfamide+mesna (HD-IFO+M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO+M over 24 h appeared to be the best tolerated. On partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.

AB - Twenty-six cycles of high-dose ifosfamide+mesna (HD-IFO+M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO+M over 24 h appeared to be the best tolerated. On partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.

KW - Breast cancer

KW - Ifosfamide+mesna

KW - Salvage therapy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0024246951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024246951&partnerID=8YFLogxK

U2 - 10.1007/BF00398184

DO - 10.1007/BF00398184

M3 - Article

C2 - 3144554

AN - SCOPUS:0024246951

VL - 114

SP - 602

EP - 604

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 6

ER -